IL6 and hemophagocytic syndrome: The most severe and hyperinflammatory cases of sepsis-associated HLH could benefit from therapies that target cytokine storms, such as anakinra (anti-IL-1), tocilizumab (anti-IL-6), and/or ruxolitinib (anti-JAK2) (16, 62, 63).